In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

An impressive array of Big Pharma backers have lined up to ensure Strand Therapeutics has the funding needed to take its mRNA ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.

A backlash against a White House video promoting deportation and Casalonga opening a new office in Düsseldorf were also among the top talking points ...

Source: Bloomberg, data from to 31 March 2025 to 30 June 2025. Returns are for the MSCI All Country World Index (ACWI) and ...

Eli Lilly and Company has acquired Verve Therapeutics Inc., a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.